Clinical trials: Allergy, Peanut
Peanut Allergy
PALISADE Follow-on Study (ARC004)
The purpose of this study is to demonstrate the safety, tolerability, and efficacy of AR101 through oral immunotherapy (OIT) in peanut-allergic children and adults who have completed the ARC003 study.
- Trial name
- NCT02993107
- Testing
- AR101
- Where
- 65 sites in United States, Canada and 7 more
- Volunteers
- 388 people
- Sponsor
- Aimmune Therapeutics, Inc.
Peanut Allergy
Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants
This is a Phase 1/2 study to evaluate the safety and clinical activity of ENP-501 in non-peanut allergic (NPA) healthy participants and participants with an established peanut allergy (PA)
- Trial name
- NCT07117669
- Testing
- ENP-501
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- N-Fold, LLC
Peanut Allergy
Oral Immunotherapy for Young Children With Peanut Allergy - Small Children OIT
Open label study with peanut oral immunotherapy (OIT). Peanut allergic children aged 1-3 years of age will be randomized 2:1 to: 1.
- Trial name
- SmaChO (NCT04511494)
- Testing
- Peanut (bamba)
- Where
- Sweden
- Volunteers
- 114 people
- Sponsor
- Karolinska Institutet
Food Allergies, Peanut Allergies
A Long Term, Observational Follow-Up Study of Children and Young People Who Underwent an 18-Month Course of Oral Immunotherapy Treatment for Peanut, Egg or Milk Allergy (5-15 Years Post-Treatment)
The goal of this observational study is to learn about the long-term outcomes of children and young people who underwent an 18-month course of oral immunotherapy (OIT) treatment for peanut, egg or milk allergy.
- Conditions
- Food Allergies, Peanut Allergies, Egg Allergy, Milk Allergy
- Trial name
- LPEM (NCT07359183)
- Where
- Australia
- Volunteers
- 147 people
- Sponsor
- Murdoch Childrens Research Institute
Peanut Allergy
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)
The purpose of this study is to demonstrate the efficacy and safety of AR101 through reduction in clinical reactivity to peanut allergen in peanut-allergic children and adults.
- Trial name
- PALISADE (NCT02635776)
- Testing
- AR101 powder provided in capsules & sachets
- Where
- 69 sites in United States, Canada and 8 more
- Volunteers
- 555 people
- Sponsor
- Aimmune Therapeutics, Inc.
Peanut Allergy
Oral Peanut Immunotherapy
Peanut allergy is one of the most serious food allergies because of its life long persistence, and the potential for severe allergic reactions.
- Trial name
- PNOIT (NCT01324401)
- Testing
- Peanut flour OIT
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Peanut Allergy
Canadian Peanut Thresholds Study
An important gap in the management of peanut allergy is that we do not know the threshold dose, below which most peanut allergic individuals will not react.
- Trial name
- NCT01812798
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- McMaster University
Peanut Allergies
Efficacy, Safety and Pharmacokinetics of LP-003 in Peanut Allergic Patients
This study will evaluate the safety and efficacy of LP-003 for an increasing the amount of peanut protein that people with a peanut allergy can tolerate without having allergic symptoms.
- Trial name
- NCT07785063
- Testing
- LP-003 Injection
- Volunteers
- 80 people
- Sponsor
- Longbio Pharma (Suzhou) Co., Ltd.
Food Hypersensitivity
Take Away Food Allergy; Inducing Tolerance in Children Allergic to Peanut
The purpose of the study is to identify prognostic markers and possible success rate of tolerance induction to peanut allergens in children allergic to peanut.
- Trial name
- NCT02457416
- Testing
- Peanut
- Where
- Norway
- Volunteers
- 77 people
- Sponsor
- Oslo University Hospital
Peanut-Induced Anaphylaxis, Peanut Allergy
UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies
This study will test a new investigational treatment called UKK-0018. UKK-0018 as an immunotherapeutic for the treatment of peanut allergies.
- Trial name
- UKK-0018 (NCT07349212)
- Testing
- UKK-0018
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 40 people
- Sponsor
- Ukko Inc
Peanut Allergies in Children
Evaluation of a Supervised Clinical Feeding Intervention
Peanut allergies affect approximately 2.5% of children; are associated with significant mortality, morbidity, and economic costs; and often lead to persistent peanut allergies in adulthood.
- Trial name
- NCT06892132
- Testing
- Supervised feeding intervention, Handout
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Boston Children's Hospital
Allergy
Study of Oral Food Challenge Biomarkers (SAFER)
This is a multi-center, mechanistic study. It is designed to learn more about signs in the body, called biomarkers, that might show if someone will have a reaction to peanut during a feeding test.
- Trial name
- SAFER (NCT07279467)
- Testing
- Oral Food Challenge (OFC): Peanut Protein
- Where
- 10 sites in United States
- Volunteers
- 500 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Allergy;Food
Relevance of Sensitization to Legumes in Children Allergic to Peanut
The objectives of this study are to determine in children allergic to peanut (i) the prevalence of sensitization to other legumes, (ii) the prevalence of allergy to each legume in patients who are sensitized to it (iii ) the…
- Trial name
- NCT04329078
- Volunteers
- 250 people
- Sponsor
- Central Hospital, Nancy, France
Peanut Hypersensitivity
Oral Immunotherapy (OIT) for Peanut Allergy
Peanut allergy is known to cause severe anaphylactic reactions.The goal of this proposal is to produce a new treatment that would benefit subjects who have peanut allergy by lowering the risk of anaphylactic reactions…
- Trial name
- PnOIT3 (NCT00815035)
- Testing
- Peanut OIT
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of North Carolina, Chapel Hill
Food Allergy, Peanut Allergy
Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy
The primary objective of this study is to determine whether allowing ingestion of sub-threshold amounts of peanut in those with a high threshold (tolerate at least 143 mg peanut protein on supervised double-blind…
- Trial name
- CAFETERIA (NCT03907397)
- Testing
- Peanut Protein, Continued peanut avoidance
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Scott Sicherer
Peanut Allergy
CNP-201 in Subjects With Peanut Allergy
This study is a Phase 1b/2a clinical trial to assess the safety, tolerability, and pharmacodynamics of multiple ascending doses (Escalation Phase) of CNP-201 with the goal of identifying a safe and tolerable dose level to be…
- Trial name
- NCT05250856
- Testing
- CNP-201
- Where
- 17 sites in United States
- Volunteers
- 15 people
- Sponsor
- COUR Pharmaceutical Development Company, Inc.
Peanut Allergy
Evaluating the Safety and Efficacy of Oral Encapsulated Fecal Microbiota Transplant in Peanut Allergic Patients
This is a Phase I trial to evaluate the safety and efficacy of oral encapsulated fecal microbiota transplantation (FMT) in the treatment of peanut allergy.
- Trial name
- NCT02960074
- Testing
- Fecal Microbiota Capsule
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Rima Rachid
Peanut Allergy
Adjuvant Treatment With Abatacept to Promote Remission During Peanut Oral Immunotherapy
This is a phase 2a, multi-center, randomized and double-blind placebo-controlled trial comparing 24 weeks of abatacept versus placebo used as adjuvant to oral immunotherapy to induce remission in adolescents and adults with…
- Trial name
- ATARI (NCT04872218)
- Testing
- Abatacept, Peanut oral immunotherapy
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- Philippe Bégin
Peanut Allergic Subjects, Peanut Allergies
Oral Immunotherapy for Children With Peanut Allergy
This clinical trial aims to investigate if oral immunotherapy can help children with peanut allergy tolerate peanut. Children aged 6 months to 4 years can take part in the trial.
- Conditions
- Peanut Allergic Subjects, Peanut Allergies, Peanut Hypersensitivity, Food Allergy Peanut
- Trial name
- NCT07895095
- Testing
- Oral immunotherapy with peanut
- Where
- 5 sites in Denmark
- Volunteers
- 56 people
- Sponsor
- Laura Ozer Kettner
Food Allergy
Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy
This study is researching an experimental drug called linvoseltamab combined with another drug called dupilumab. The study is looking at patients who have severe IgE-mediated food allergy.
- Trial name
- NCT06369467
- Testing
- linvoseltamab, dupilumab
- Where
- 5 sites in United States
- Volunteers
- 6 people
- Sponsor
- Regeneron Pharmaceuticals